nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—MAP2K2—CXCR3-mediated signaling events—CXCL11—nasal cavity cancer	0.0521	0.0521	CbGpPWpGaD
Trametinib—MAP2K1—CXCR3-mediated signaling events—CXCL11—nasal cavity cancer	0.0487	0.0487	CbGpPWpGaD
Trametinib—MAP2K2—Frs2-mediated activation—FRS2—nasal cavity cancer	0.0429	0.0429	CbGpPWpGaD
Trametinib—MAP2K2—Prolonged ERK activation events—FRS2—nasal cavity cancer	0.0404	0.0404	CbGpPWpGaD
Trametinib—MAP2K1—Frs2-mediated activation—FRS2—nasal cavity cancer	0.0402	0.0402	CbGpPWpGaD
Trametinib—MAP2K1—Prolonged ERK activation events—FRS2—nasal cavity cancer	0.0378	0.0378	CbGpPWpGaD
Trametinib—MAP2K2—FRS2-mediated cascade—FRS2—nasal cavity cancer	0.0273	0.0273	CbGpPWpGaD
Trametinib—MAP2K2—Signalling to ERKs—FRS2—nasal cavity cancer	0.0273	0.0273	CbGpPWpGaD
Trametinib—MAP2K1—FRS2-mediated cascade—FRS2—nasal cavity cancer	0.0255	0.0255	CbGpPWpGaD
Trametinib—MAP2K1—Signalling to ERKs—FRS2—nasal cavity cancer	0.0255	0.0255	CbGpPWpGaD
Trametinib—MAP2K2—Toll-like Receptor Signaling Pathway—CXCL11—nasal cavity cancer	0.0236	0.0236	CbGpPWpGaD
Trametinib—MAP2K1—Toll-like Receptor Signaling Pathway—CXCL11—nasal cavity cancer	0.0221	0.0221	CbGpPWpGaD
Trametinib—MAP2K2—SHP2 signaling—FRS2—nasal cavity cancer	0.0219	0.0219	CbGpPWpGaD
Trametinib—MAP2K1—SHP2 signaling—FRS2—nasal cavity cancer	0.0205	0.0205	CbGpPWpGaD
Trametinib—MAP2K1—Neurotrophic factor-mediated Trk receptor signaling—FRS2—nasal cavity cancer	0.0197	0.0197	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—CXCL11—nasal cavity cancer	0.0185	0.0185	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—CXCL11—nasal cavity cancer	0.0173	0.0173	CbGpPWpGaD
Trametinib—MAP2K2—IRS-mediated signalling—FRS2—nasal cavity cancer	0.0161	0.0161	CbGpPWpGaD
Trametinib—MAP2K2—IRS-related events—FRS2—nasal cavity cancer	0.0157	0.0157	CbGpPWpGaD
Trametinib—MAP2K2—IRS-related events triggered by IGF1R—FRS2—nasal cavity cancer	0.0155	0.0155	CbGpPWpGaD
Trametinib—MAP2K2—IGF1R signaling cascade—FRS2—nasal cavity cancer	0.0151	0.0151	CbGpPWpGaD
Trametinib—MAP2K2—Insulin receptor signalling cascade—FRS2—nasal cavity cancer	0.0151	0.0151	CbGpPWpGaD
Trametinib—MAP2K1—IRS-mediated signalling—FRS2—nasal cavity cancer	0.0151	0.0151	CbGpPWpGaD
Trametinib—MAP2K1—IRS-related events—FRS2—nasal cavity cancer	0.0147	0.0147	CbGpPWpGaD
Trametinib—MAP2K1—IRS-related events triggered by IGF1R—FRS2—nasal cavity cancer	0.0145	0.0145	CbGpPWpGaD
Trametinib—MAP2K1—IGF1R signaling cascade—FRS2—nasal cavity cancer	0.0142	0.0142	CbGpPWpGaD
Trametinib—MAP2K1—Insulin receptor signalling cascade—FRS2—nasal cavity cancer	0.0142	0.0142	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by Insulin receptor—FRS2—nasal cavity cancer	0.0126	0.0126	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by Insulin receptor—FRS2—nasal cavity cancer	0.0118	0.0118	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.0108	0.0108	CbGpPWpGaD
Trametinib—MAP2K2—BDNF signaling pathway—FRS2—nasal cavity cancer	0.0106	0.0106	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.0103	0.0103	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—FRS2—nasal cavity cancer	0.0101	0.0101	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.0101	0.0101	CbGpPWpGaD
Trametinib—MAP2K1—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00989	0.00989	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—FRS2—nasal cavity cancer	0.00967	0.00967	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00963	0.00963	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—FRS2—nasal cavity cancer	0.00962	0.00962	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00958	0.00958	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—FRS2—nasal cavity cancer	0.00953	0.00953	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00948	0.00948	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—FRS2—nasal cavity cancer	0.00905	0.00905	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—FRS2—nasal cavity cancer	0.009	0.009	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—FRS2—nasal cavity cancer	0.00897	0.00897	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00897	0.00897	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00897	0.00897	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00896	0.00896	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—FRS2—nasal cavity cancer	0.00892	0.00892	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—FRS2—nasal cavity cancer	0.00889	0.00889	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00881	0.00881	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—FRS2—nasal cavity cancer	0.00877	0.00877	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00839	0.00839	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00839	0.00839	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—FRS2—nasal cavity cancer	0.00839	0.00839	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—FRS2—nasal cavity cancer	0.00831	0.00831	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00824	0.00824	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—FRS2—nasal cavity cancer	0.0082	0.0082	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00794	0.00794	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00743	0.00743	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—FRS2—nasal cavity cancer	0.00611	0.00611	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—FRS2—nasal cavity cancer	0.00571	0.00571	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00377	0.00377	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00353	0.00353	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—FRS2—nasal cavity cancer	0.00348	0.00348	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—FRS2—nasal cavity cancer	0.00326	0.00326	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00223	0.00223	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00208	0.00208	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—FRS2—nasal cavity cancer	0.00203	0.00203	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—FRS2—nasal cavity cancer	0.0019	0.0019	CbGpPWpGaD
Trametinib—MAP2K2—Disease—FRS2—nasal cavity cancer	0.00187	0.00187	CbGpPWpGaD
Trametinib—MAP2K1—Disease—FRS2—nasal cavity cancer	0.00175	0.00175	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FRS2—nasal cavity cancer	0.00131	0.00131	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FRS2—nasal cavity cancer	0.00123	0.00123	CbGpPWpGaD
